Comparing Black and White Patients in Treatment of Advanced Prostate Cancer and Survival in an Equal Access Health System

被引:0
|
作者
Eaglehouse, Yvonne L. [1 ,2 ]
Darmon, Sarah [1 ,2 ]
Chesnut, Gregory T. [1 ]
Shriver, Craig D. [1 ,3 ]
Zhu, Kangmin [1 ,2 ,4 ]
机构
[1] Uniformed Serv Univ Hlth Sci USUHS, Murtha Canc Ctr Res Program, Dept Surg, 6720A Rockledge Dr,Suite 310, Bethesda, MD 20817 USA
[2] Henry M Jackson Fdn Advancement Mil Med Inc, Bethesda, MD 20817 USA
[3] Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD USA
[4] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA
关键词
Prostate cancer; Cancer treatment; Racial disparities; Prostate cancer survival; Surgical oncology; MEN;
D O I
10.1007/s40615-024-02217-4
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundRacial disparities in prostate cancer treatment and survival in the U.S. have been attributed to differences in access to care and medical insurance. We aimed to compare treatment and survival of advanced prostate cancers between White and Black men in the equal access Military Health System (MHS).MethodsWe accessed the MilCanEpi database to study a cohort of non-Hispanic White and Black men diagnosed with stage III or IV prostate cancer between 1998 and 2014 in the MHS. The racial groups were compared in receiving curative treatment of radical prostatectomy (RP) only, RP with (neo)adjuvant radiation or hormone therapy, radiation only, or combination radiation and hormone therapy; and overall survival using multivariable regression models.ResultsThe study included 1476 White and 531 Black men. Overall, there was no racial difference in receiving any curative treatment (AOR = 0.85, 95% CI = 0.67, 1.08 for Black vs. White). By treatment type, Black men were statistically as likely to receive RP only (AOR = 0.87, 95% CI = 0.67, 1.14), radiation only (AOR = 0.81, 95% CI = 0.49, 1.34), or combination radiation and hormone therapy (AOR = 1.12, 95% CI = 0.71, 1.78) but statistically less likely to receive RP with (neo)adjuvant treatment (AOR = 0.56, 95% CI = 0.37, 0.86) relative to no curative treatment compared to White men. The difference in RP with (neo)adjuvant treatment was also statistically significant among patients with stage III tumors, but not stage IV. Survival was similar overall (AHR = 1.12, 95% CI = 0.88, 1.42 for Black vs. White) and when evaluated by tumor stage.ConclusionsIn the MHS, the overall likelihood to receive any treatment for advanced prostate cancers and survival was similar between races, which might result from universal health care. Racial differences in receipt of RP with (neo)adjuvant treatment, especially for patients with stage III prostate cancer, may be related to factors other than access to care and warrants further research.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The health system and access to treatment in patients with cervical cancer in Mexico
    Arango-Bravo, Eder A.
    del Carmen Cetina-Perez, Lucely
    Galicia-Carmona, Tatiana
    Castro-Eguiluz, Denisse
    Gallardo-Rincon, Dolores
    Cruz-Bautista, Ivette
    Duenas-Gonzalez, Alfonso
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Racial disparities in treatment patterns for localized prostate cancer in an equal access system: What are we missing?
    Fabio Crocerossa
    M. Carmen Mir
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 216 - 217
  • [33] Racial disparities in treatment patterns for localized prostate cancer in an equal access system: What are we missing?
    Crocerossa, Fabio
    Mir, M. Carmen
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (02) : 216 - 217
  • [34] Equal access to health care reduces racial disparities in prostate cancer outcomes
    Hoge, Connor G.
    Sussman, Jonathan
    Sidana, Abhinav
    CANCER, 2020, 126 (18) : 4256 - 4257
  • [35] Trends and black/white differences in treatment for nonmetastatic prostate cancer
    Klabunde, CN
    Potosky, AL
    Harlan, LC
    Kramer, BS
    MEDICAL CARE, 1998, 36 (09) : 1337 - 1348
  • [36] RADIATION-TREATED CARCINOMA OF PROSTATE - COMPARISON OF SURVIVAL OF BLACK AND WHITE PATIENTS BY GLEASONS GRADING SYSTEM
    AZIZ, H
    ROTMAN, M
    THELMO, W
    CHEN, P
    CHOI, KN
    KHIL, SU
    LAUNGANI, GB
    BRANDYS, M
    AYR, G
    MACCHIA, RJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (02): : 166 - 171
  • [37] Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting
    Moul, JW
    Douglas, TH
    McCarthy, WF
    McLeod, DG
    JOURNAL OF UROLOGY, 1996, 155 (05): : 1667 - 1672
  • [38] Impact of Socioeconomic Status (SES) on Head and Neck Cancer (HNC) Survival in an Equal Access Health Care System
    Chu, K. P.
    Habbous, S.
    Huang, S.
    Cheng, L.
    Hope, A.
    Xu, W.
    O'Sullivan, B.
    Waldron, J.
    Chang, E. T.
    Liu, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S107 - S108
  • [39] Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system
    Anderson, Eric M.
    Gu, Lin
    Oyekunle, Taofik
    De Hoedt, Amanda M.
    Wiggins, Emily
    Gay, Christopher J.
    Lu, Diana J.
    Daskivich, Timothy J.
    Freedland, Stephen J.
    Zumsteg, Zachary S.
    Csizmadi, Ilona
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 593 - 595
  • [40] Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system
    Eric M. Anderson
    Lin Gu
    Taofik Oyekunle
    Amanda M. De Hoedt
    Emily Wiggins
    Christopher J. Gay
    Diana J. Lu
    Timothy J. Daskivich
    Stephen J. Freedland
    Zachary S. Zumsteg
    Ilona Csizmadi
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 593 - 595